A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Today’s international health interventions—like colonial treatment campaigns—can be well-intentioned and still oppress and harm people they try to serve. Grasp of imperial medical history is critical for helping global health professionals understand the contexts in which they practice.
AMA J Ethics. 2016;18(7):743-753. doi:
10.1001/journalofethics.2016.18.7.mhst1-1607.
Since the 1960s, drug names have been products of complex, multiparty negotiations in which interests of patients, pharmaceutical firms, clinicians, and US and international regulators must be balanced.
AMA J Ethics. 2019;21(8):E686-696. doi:
10.1001/amajethics.2019.686.
One patient’s experience of life-encompassing iatrogenic harm from being institutionalized emphasizes Italy’s comparative success, relative to the United States, in recovering from decades of deinstitutionalization policy.
AMA J Ethics. 2022;24(8):E795-803. doi:
10.1001/amajethics.2022.795.
Physicians tend to rely on diagnostic criteria, including BMI, that can influence patients’ access to care, referrals, and insurance coverage for indicated interventions.
AMA J Ethics. 2023;25(7):E507-513. doi:
10.1001/amajethics.2023.507.
Erica Chou, MD, Thomas Grawey, DO, and Jane B. Paige, PhD
Biases rooted in historically entrenched assumptions about medical supremacy are reified in popular cultural representations of health professionals and in students’ lived experiences.
AMA J Ethics. 2023;25(5):E338-343. doi:
10.1001/amajethics.2023.338.